about
Molecular mechanism of action of metformin: old or new insights?Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and ureaβ2-adrenergic regulation of stress hyperglycemia following hemorrhage in the obese Zucker rat.The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issue.EphA4 Receptor Forward Signaling Inhibits Glucagon Secretion From α-Cells.Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.Attenuated mesangial cell proliferation related to store-operated Ca2+ entry in aged rat: the role of STIM 1 and Orai 1Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus.GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects.Mathematical modelling of local calcium and regulated exocytosis during inhibition and stimulation of glucagon secretion from pancreatic alpha-cells.A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
P2860
Q22252798-2863180F-7583-4030-94CF-5FBE108A7348Q28085593-A5D489F2-1C8A-4B63-8F65-F19D42FD7D02Q35094140-1D905A3A-408F-4882-A8B3-CA435D98ABAFQ35760275-3466B0F4-2549-49DA-8954-8EC8C6BB4D8EQ36186236-46BFF040-6358-4565-A710-488B2294524FQ36972891-DDC5668B-98C5-4A2C-9B1C-48BB266FF4A7Q37300531-87EF5003-93C3-491D-BE42-942F26541444Q37561118-4870582F-CF1F-453B-A226-2FD46BDE6601Q38055195-82525462-E49B-4D6B-B46C-DD7C16DA428DQ47566343-62F3B817-1387-42AB-961B-EFEE0D220274Q50491281-25E48BDE-B9BD-4BC2-BA4E-11AA01FB5D10Q50872287-F1B02783-DEB6-44DF-A3C0-480C5353E737Q51754121-58D10A8B-1E0E-47FA-997C-B42A5F886549
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
The alpha-cell as target for type 2 diabetes therapy.
@en
The alpha-cell as target for type 2 diabetes therapy.
@nl
type
label
The alpha-cell as target for type 2 diabetes therapy.
@en
The alpha-cell as target for type 2 diabetes therapy.
@nl
prefLabel
The alpha-cell as target for type 2 diabetes therapy.
@en
The alpha-cell as target for type 2 diabetes therapy.
@nl
P2860
P50
P356
P1476
The alpha-cell as target for type 2 diabetes therapy
@en
P2093
Tina Vilsbøll
P2860
P304
P356
10.1900/RDS.2011.8.369
P577
2011-11-10T00:00:00Z